Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEORX(nerx) -- Ignore unavailable to you. Want to Upgrade?

To: priceguy who wrote (560)	12/13/1999 4:24:00 PM
From: OldAIMGuy	Read Replies (2) \| Respond to of 661

Hi Ron and thanks, Priceguy's comments are valid regarding the technical aspects of what that report said. However, after spending a good portion of the last decade "decoding" NERX's news releases, I'd say that one was very good news. The whole "pretarget" idea of binding an agent to the "nasties" and then sending in the toxin to attach to the binding agent is clever. It allows the toxin to be introduced in very low total dosage while making sure it binds to the "nasties." The body then flushes away the rest of the toxin very quickly, doing very little damage to non-afflicted tissue. In this case it would appear that they've developed a cute little bug to produce a very good binding agent. Being better at what it is asked to do allows the dosage of the toxin to be reduced even further while still being effective. Of course the effectiveness is what this is all about. In the news article they mention that some lymphoma patients are showing complete success. It's still a long way until the cash register starts ringing loud and clear, but the science keeps getting better. Investors will be more willing to take a chance on the wait as this continues. Best regards, Tom PS: We'll see if my version helps to lift the stock!! :-)